An erroneous transcriptional process, known as molecular misreading, gives rise to an alternative transcript of the ubiquitin B (UBB) gene. This transcript encodes the protein UBB
Although most polyubiquitylated proteins are rapidly degraded by the proteasome, some can resist proteasomal degradation (1) . For example, the glycine-alanine repeat of the Epstein-Barr virus, which is responsible for infectious mononucleosis (2) , and the expanded polyglutamine repeats found in some neurodegenerative diseases (3, 4) hinder proteasomal degradation. Moreover, the ubiquitin binding domains of polyubiquitin shuttling factor Rad23 (5) and the transcription factor Met4 (6) render these proteins resistant to proteasomal degradation. Another protein that is poorly degraded despite the presence of a potentially efficient degradation signal is UBB
ϩ1
, an aberrant product of the ubiquitin precursor gene UBB (7) . As a consequence of a transcriptional erroneous process, known as molecular misreading, UBB transcripts with a dinucleotide deletion are generated at very low frequency (8) . The open reading frame of these aberrant transcripts encodes the first ubiquitin monomer with the C-terminal glycine substituted for a tyrosine, followed by a 19-aa extension encoded by the frame-shifted open reading frame. Levels of UBB ϩ1 are very low under normal conditions, but the protein tends to accumulate specifically in affected cells in several neurodegenerative diseases, including Alzheimer's disease and Huntington's disease (9, 10) , as well as in several non-neuronal pathologies characterized by the presence of misfolded proteins such as liver pathologies (11, 12) and sporadic inclusion-body myositis muscle fibers (13) . A recent study suggests that UBB ϩ1 may be important for ␤-amyloid-induced neurotoxicity (14) . UBB ϩ1 structurally resembles a ubiquitin fusion degradation (UFD) substrate (7) . This class of substrates is characterized by the presence of an N-terminal ubiquitin moiety that cannot be removed by general deubiquitylation enzymes. Since the lysine residues at positions 29 and 48 of the ubiquitin moiety function as acceptors for polyubiquitin chains, these fusions are normally rapidly degraded by the 26S proteasome (15) . While UFD substrates have been generally engineered to target proteins of interest for proteasomal degradation (15) (16) (17) (18) , UBB ϩ1 is to our knowledge the only identified naturally occurring UFD substrate at this time. It is noteworthy that proteasome substrates, which are subject to N-terminal ubiquitylation, form an intermediate that structurally resembles UFD substrates (19) . Yet, unlike other UFD or N-terminal ubiquitylated proteasome substrates, UBB ϩ1 tends to accumulate to high levels under stress conditions when the capacity of the ubiquitin/proteasome system is challenged (20) . In line with this notion, at elevated levels UBB ϩ1 is a stable protein that causes general impairment of the ubiquitin/proteasome system, resulting in cell cycle arrest and apoptosis (7, 21) . It has been suggested that the presence of UBB ϩ1 in human tissue may be a surrogate marker for impairment of the ubiquitin/proteasome system (8) . Thus, cell populations that contain UBB ϩ1 may do so as a consequence of ubiquitin/proteasome system dysfunction encountered in the course of the pathology (22) . At the same time, it is clear that elevated UBB ϩ1 levels inhibit the ubiquitin/proteasome system (7, 23) , suggesting that a positive feedback loop may occur in which the already compromised ubiquitin/proteasome system is further inhibited due to the accumulated UBB . Although the molecular mechanism for UBB ϩ1 -mediated proteasome dysfunction remains unclear, an in vitro study suggests that ubiquitylated recombinant UBB ϩ1 may resemble unanchored polyubiquitin chains (24) . Indeed, in cell lines the inhibitory activity of UBB ϩ1 depends on the presence of the lysine residues at positions 29 and 48, which are the two lysine residues in ubiquitin that can form polyubiquitin chains targeting for proteasomal degradation (7) .
In the present study, we investigated the cause for the unusual stability of UBB ϩ1 and show that the C-terminal extension of UBB ϩ1 is not sufficiently long to be adequately handled by the proteasome. These data give new insights into the molecular constraints for efficient proteasomal degradation and provide an attractive explanation for the unusual stability of UBB ϩ1 .
MATERIALS AND METHODS

Construction of plasmids
All open reading frames were expressed from a CMV promoter in the mammalian expression vectors pCMV-myc (Clontech, Palo Alto, CA, USA) or EGFP-N1 (Clontech). The ubiquitin open reading frame and C-terminal extensions were PCRamplified from Ub
G76V
-GFP and cloned in frame in pCMV-myc. Nonfluorescent green fluorescent protein (nfGFP) was constructed by introducing the amino acid substitution Y67R in the chromophore of GFP (7 
Transfections and tissue culture
The human cervical carcinoma HeLa cell lines and neuroblastoma SH-SY5Y cell lines were cultured in Dulbecco's modified Eagle medium (Life Technologies, Inc., Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (Life Technologies, Inc.), 10 U/ml penicillin, and 10 g/ml streptomycin. Medium for SH-SY5Y cells was also supplemented with 5 ml nonessential amino acids (Life Technologies, Inc.) and 2 mM l-glutamine (Life Technologies, Inc.). Cells were transiently transfected with polyethylenimine (Polysciences, Warrington, PA, USA) or lipofectamine (Life Technologies) and analyzed at indicated time points. Where indicated, cells were incubated for 17 h with medium containing 1 M of the highly specific proteasome inhibitor Z-Leu-Leu-Leu-B(OH) 2 (MG262; Biomol, Plymouth Meeting, PA, USA).
Western blot analysis
Total lysates were separated by SDS-PAGE and transferred to polyvinylide difluoride (PVDF) filters (Millipore, Bedford, MA, USA). The filters were blocked in phosphate-buffered saline supplemented with 5% skim milk and 0.1% Tween-20 and incubated with a mouse monoclonal antibody specific to c-myc (9E10; Santa Cruz Biotechnology, Santa Cruz, CA, USA) in a 1:1000 dilution for 1 h, a polyclonal antibody against UBB ϩ1 in a 1:1000 dilution for 2 h (Ubi-3 050897; gift from Dr. Fred van Leeuwen, Maastricht University, Maastricht, The Netherlands) (10), or a mixed monoclonal antibody against GFP (Roche, Mannheim, Germany) in a 1:2000 dilution for 1 h. For loading controls, blots were probed with a mouse monoclonal GAPDH (RDI Research Diagnostics, Concord, MA, USA) or ␤-actin antibody (Abcam, Cambridge, MA, USA). After subsequent washing steps and incubation with peroxidase-conjugated goat anti-mouse serum or a peroxidase-conjugated goat anti-rabbit serum (Amersham Biosciences, Piscataway, NJ, USA), the blots were developed by enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech). Western blots were quantified with ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Fluorescence microscopy and flow cytometry
For fluorescence microscopy, cells were fixed with 4% paraformaldehyde in phosphate-buffered saline solution. Cells were stained with a mouse monoclonal antibody specific to c-myc (9E10) in a 1:250 dilution followed by AlexaFluor 546 labeled anti-mouse immunoglobulins (Molecular Probes, Eugene, OR, USA) in a 1:1000 dilution. The cells were examined with a LSM510 META confocal laser scanning microscope (Zeiss, New York, NY). For analysis by flow cytometry, cells were harvested and fixed with cytofix/cytoperm (BD Biosciences, San Jose, CA, USA), followed by washing with perm/wash (BD Biosciences). The cells were either stained with the anti-c-myc mouse monoclonal antibody followed by APC-labeled goat anti-mouse immunoglobulins (BD Biosciences Pharmingen), or cotransfected with an expression plasmid of human CD8␣ (gift from Dr. J. Neefjes, Netherlands Cancer Institute, Amsterdam, The Netherlands), and stained with an APC-labeled anti-human CD8␣ antibody (BD Pharmingen). Flow cytometry was performed with a FACSort flow cytometer and analyzed with CellQuest software (Becton & Dickinson, Franklin Lakes, NJ, USA).
Protein turnover analysis
Transiently transfected HeLa cells were incubated in methionine/cysteine-free RPMI medium (Sigma, St. Louis, MO, USA) and then metabolically labeled with 40 Ci [
35 S] methionine/cysteine (Redivue PRO-MIX 35 S, Amersham Biosciences) for 30 min at 37°C. After the labeling period, cells were washed and incubated with RPMI medium supplemented with 10 mM methionine and 1 mM cysteine. Cells were harvested at the indicated time points in lysis buffer containing 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholic acid, 0.1% SDS, 50 mM Tris-HCl pH 8, 20 mM N-ethylmaleimide (Sigma), and complete protease inhibitor cocktail (Roche) and were lysed for 1 h at 4°C. Lysates were centrifuged at 14,000 rpm for 10 min at 4°C, and the supernatant was used for immunoprecipitation. Myc-tagged proteins were immunoprecipitated for 1 h at 4°C with a mouse monoclonal antibody specific to c-myc (9E10, Santa Cruz Biotechnology) in a 1:50 dilution, followed by incubation with protein-G Sepharose beads (Amersham Bioscience) for 2 h at 4°C. Quantification of the pulse-chase experiments was performed with ImageJ software.
Yeast experiments
All experiments were performed with a haploid derivative of S. cerevisiae strain DF5 (lys2-801, leu2-3, -112, ura3-52, his3-⌬200, trp1-1, Mat-a). Yeast transformed with episomal pYES2 plasmids encoding the indicated UFD substrates was grown successively overnight in synthetic minimal medium with glucose, raffinose, or galactose as sole carbohydrate source. Protein turnover was determined by administration of 0.5 mg/ml cycloheximide to the yeast cultures in midlog phase and harvesting samples at the indicated times for Western blot analysis. Total protein extracts were obtained by precipitation in 12.5% trichloroacetic acid. For proteasome inhibition experiments, yeast was grown for 1 h in the presence of 50 M proteasome inhibitor Z-Leu-Leu-Leu-CHO (MG132; Biomol). To allow uptake of the inhibitor, yeast was grown in synthetic medium with 0.1% proline as sole nitrogen source and proteasome inhibitor was added together with 0.003% SDS when the culture had reached an OD 600 of 0.5 (25) .
RESULTS
The ؉1 extension does not function as a modular stabilization signal
Since certain domains can counteract degradation signals and protect proteins from proteasomal degradation (2, 4 -6), we investigated whether the 19-aa Cterminal extension of UBB ϩ1 had intrinsic stabilizing properties that could account for the stable nature of UBB ϩ1 . For clarity we will refer hereafter to the Cterminal 19 aa as the "ϩ1 extension" (Fig. 1A) . Since the C-terminal part is translated from a frame-shifted open reading frame and likely to lack any higher-order structure, we considered it feasible that the ϩ1 extension rendered UBB ϩ1 aggregation prone, which is a robust way to block proteasomal degradation (4) and impair the ubiquitin/proteasome system (26) .
To probe into this possibility, we fused the ϩ1 extension to GFP-based proteasome substrates carrying well-defined degradation signals (Fig. 1B) . Insertion of the ϩ1 extension at the C termini of either the Ub G76V -GFP or Ub-R-GFP proteasome substrates did not increase their steady-state levels nor did it inhibit their accumulation in response to the proteasome inhibitor MG262 as determined by flow cytometry (Fig. 1C, D) and Western blot analysis (data not shown). We conclude that the ϩ1 extension does not have intrinsic stabilizing properties.
Stability of UBB
؉1 is attributed to the length and not the primary amino acid sequence of the ؉1 extension Several full-sized proteins such as ␤-galactosidase (15), luciferase (17) , and fluorescent proteins (16) have been successfully fused to uncleavable ubiquitin moieties, which resulted in short-lived UFD substrates. A striking difference between UBB ϩ1 and these shortlived UFD substrates is the limited length of the Cterminal extension of UBB ϩ1 . We wondered, therefore, whether this feature could be the reason for the poor degradation of UBB
ϩ1
. To address this issue, we truncated the short-lived Ub G76V -GFP reporter substrate to obtain a UFD substrate that had an extension of the same length as the ϩ1 extension but an otherwise unrelated sequence ( Fig. 2A ). An N-terminal myc epitope tag was introduced in order to distinguish this ubiquitin fusion from the general pool of free or conjugated ubiquitin in the cells. We noted that the expression vector used for this purpose gave rise to higher expression levels than the construct used in our previous study (7) , which was accompanied by increased steady-state levels and enhanced stability of UBB ϩ1 (Supplemental Fig. 1 ). Since it has been previously shown that expression levels are important, as cells can turn over low levels of UBB ϩ1 but fail to degrade slightly elevated levels of UBB ϩ1 (27) , we introduced all fusions in the same pCMV-Myc expression vector.
HeLa cells were transiently transfected with myc UBB ϩ1 , myc Ub-19aa, and myc Ub G76V -nfGFP (a nonfluorescent GFP was used in this context to allow analysis of its trans inhibitory effect in cell lines expressing GFP-based reporter substrates; see below). Flow cytometric analysis of transiently transfected HeLa cells showed a clear increase in the levels of the short-lived myc Ub G76V -nfGFP protein after treatment with proteasome inhibitor, which confirmed that this fusion is turned over by proteasomal degradation (Fig. 2B) . In contrast myc UBB ϩ1 and myc Ub19aa were relatively stable and did not accumulate on proteasome inhibitor administration, suggesting that they were not degraded by the proteasome (Fig. 2B) . Thus, a UFD substrate with a 19-aa extension that was unrelated to the original extension derived from the ϩ1 frameshift was stable, which suggests that the unusual stability of UBB ϩ1 is due to the length of the extension and not to its primary amino acid sequence. (For clarity, we will refer to both short-lived and long-lived ubiquitin fusions as "UFD substrates," even though the latter are not degraded by the proteasome, and hence cannot be considered as true proteasome substrates.)
We hypothesized that a 19-aa extension following a ubiquitin domain is too short to support efficient degradation rendering UBB ϩ1 and myc Ub-19aa as stable proteins. To test this hypothesis, we made a set of UFD substrates in which we extended the C terminus stepwise by adding 5 aa at a time ( Fig. 2A) .
myc UBB ϩ1 and the UFD substrates with extensions of 19 and 20 aa were not efficiently degraded by the proteasome (Fig. 2C) . In contrast, UFD substrates with a 25-or 30-aa extension accumulated in the presence of proteasome inhibitor, suggesting that these ubiquitin fusions are subject to proteasomal degradation (Fig. 2C) . Pulse-chase analysis with metabolically labeled cells confirmed that
Ub-19aa, and myc Ub-20aa were stable during the 4 h chase period (Fig. 2D) , whereas myc Ub25aa was rapidly degraded, with a half-life of ϳ25 min (Fig. 2E) . Further extending the C-terminal part had only a modest effect on degradation rates. Half-lives of ϳ25 and 20 min were measured for myc Ub-30aa and myc Ub G76V -nfGFP, respectively (Fig. 2E) . These results point to a threshold at around 25 aa: substrates with shorter extension are stable, whereas substrates with a longer extension are rapidly degraded by the proteasome.
In order to study whether the length-dependent stability of ubiquitin fusions is a general phenomenon applying for different types of cells, we analyzed the stability of these UFD substrates in the human neuroblastoma cell line SH-SY5Y. The neuroblastoma cell lines were transiently transfected with plasmids encoding myc UBB ϩ1 , myc Ub-20aa, and myc Ub-25aa. We found that also in this cell line the myc Ub-25aa was present at very low levels and accumulated readily in the presence of proteasome inhibitor, demonstrating that this UFD substrate is rapidly degraded in neuroblastoma cells (Fig. 2F) . In contrast, steady-state levels of myc UBB ϩ1 and myc Ub-20aa were high and showed only a minor increase in the presence of proteasome inhibitor in line with poor proteasomal degradation of these substrates. Thus, the UFD substrates display a similar length dependency in human cervix carcinoma cells and neuroblastoma cells.
Inefficient degradation of UFD substrates correlates with impairment of the ubiquitin/proteasome system
The inhibitory effect of UBB ϩ1 may arise from its unusual stability by engaging the proteasome or other components of the ubiquitin/proteasome system in a dead-end process of attempting to degrade a ubiquitylated protein that is inherently stable. This hypothesis predicts that any UFD substrate that is too short to be efficiently degraded should impair the ubiquitin/proteasome system. To address this issue, we used a reporter cell line that stably expresses the Ub G76V -GFP reporter substrate (16) . Ub G76V -GFP reporter cells were transfected with expression plasmids encoding the stable myc Ub-20aa or the unstable myc Ub-25aa fusions. In many cells the expression of myc Ub-20aa was accompanied by elevated Ub G76V -GFP levels, which suggests an impaired ubiquitin/proteasome system (Fig. 3A, top  panel) . The effect was similar to that previously found for ectopically expressed UBB ϩ1 (ref. 7 and data not shown). In contrast, fewer myc-positive cells were observed when transfected with the myc Ub-25aa-expressing plasmid, in line with the notion that this substrate is degraded by the proteasome. More important, we did not observe elevated Ub G76V -GFP levels in cells that expressed myc Ub-25aa, indicative of an operative ubiquitin/proteasome system (Fig. 3A, bottom  panel) . Also myc Ub-30aa and myc Ub G76V -nfGFP did not cause accumulation of reporter substrates (data not shown).
To obtain more quantitative data on the inhibitory Ub-20aa a major fraction of the transfected cells (as identified by CD8␣ expression) had an impaired ubiquitin/proteasome system and accumulated the reporter (Fig. 3B, top panel) . On the contrary, in cells transfected with myc Ub-25aa/CD8␣, only a very small fraction of transfected cells had detectable levels of the reporter (Fig. 3B, bottom panel) . Quantitative analysis of three independent experiments clearly showed that myc UBB ϩ1 and myc Ub-20aa had similar inhib- -nfGFP did not block the ubiquitin/proteasome system (Fig. 3C) .
We tested the length-dependent inhibitory effect of ubiquitin fusions also in human neuroblastoma cell line SH-SY5Y stably expressing the UFD reporter substrate Ub G76V -GFP or the N-end rule reporter substrate Ub-R-GFP (16) . Microscopic analysis showed that myc UBB ϩ1 and myc Ub-20aa impaired the ubiquitin/proteasome system in a large fraction of the transfected neuroblastoma cells, evidenced by the accumulation of reporter substrates, whereas the ubiquitin/proteasome system in cells expressing myc Ub-25aa remained active (Fig. 3D ). Quantitative analysis of 3 independent experiments confirmed a significant increase in cells with impaired ubiquitin/proteasome system in the myc UBB ϩ1 -and myc Ub-20aa-expressing cells (Fig. 3E) . Similar results were obtained for the neuroblastoma cell line expressing the N-end rule reporter substrate Ub-R-GFP, suggesting that the inhibitory effect is not limited to the UFD pathway (Supplemental Fig. 2) . We conclude that accumulation of a UFD substrate that is too short to be rapidly degraded can impair the ubiquitin/proteasome system.
The length dependency of proteasomal degradation of UFD substrates is conserved in budding yeast
Although the original goal of our study was to understand the unusual stability of UBB , and its relation to the inhibitory effect of UBB ϩ1 in human cells, we felt that the length-dependent degradation of UFD fusions revealed in this study could shed also light on the molecular mechanisms underlying proteasomal degradation. To investigate whether the molecular mechanisms responsible for the length constraints of UFD substrates are conserved in eukaryotes, we turned to the budding yeast S. cerevisiae. Notably, UBB ϩ1 or similar natural ubiquitin fusions have not been described for yeast. The myc Ub-20aa and myc Ub-25aa substrates were expressed in yeast from an episomal plasmid under the control of the GAL1 promoter. Western blot analysis revealed a striking difference in the steady-state levels of the two UFD substrates (Fig. 4A) . Similar to what was observed in mammalian cells, the steady-state levels of myc Ub-20aa were much higher than those of myc Ub25aa. Treatment with the proteasome inhibitor MG132 caused an increase in the myc Ub-25aa levels, confirming that the low steady-state levels of this fusion are caused by proteasomal degradation (Fig. 4A) . Analysis of their biological half-lives confirmed that myc Ub-25aa was rapidly turned over, whereas the myc Ub-20aa was stable over the analyzed 40-min timeframe (Fig. 4B, C) .
We next investigated whether the length dependency of UFD substrates is a general phenomenon by using an unrelated extension. For this purpose, we used the commonly used V5 epitope tag, which was introduced at the C terminus of the ubiquitin G76V moiety. We generated fusions with extensions of 15, 20, and 25 aa of the V5 epitope tag (Fig. 4D) . Again we found a profound difference in the steady state, with the levels of myc Ub-(V5)15aa far exceeding the myc Ub-(V5)20aa and myc Ub-(V5)25aa levels, which suggests that the critical threshold for this extension is around 15 to 20 aa, slightly shorter than the extension used in the earlier experiments (Fig. 4E and data not shown) . Moreover, the myc Ub-(V5)-20aa levels increased in response to proteasome inhibitor, consistent with the notion that the fusion is degraded by the proteasome (Fig. 4E) . In line with the low steady-state levels of the myc Ub-(V5)25aa and myc Ub-(V5)20aa fusions, we found that these fusions were rapidly degraded, whereas the myc Ub-(V5)15aa was stable (Fig. 4F, G and data not  shown) . Together, these data show that the length dependency for degradation of UFD substrates is a general and conserved phenomenon. At the same time, these data suggest that the primary amino acid sequence of the extension may modulate the length required to accommodate degradation.
A short extension converts UBB
؉1 into an efficient proteasome substrate
Our data predict that extending the tail of UBB ϩ1 with a few amino acids will allow efficient proteasomal degradation (Fig. 5A) . Indeed, we found that expression of myc UBB ϩ1 -6aa resulted in a low steady-state level of the fusion that was increased on administration of proteasome inhibitor, whereas myc UBB ϩ1 was stable (Fig. 5B) . Turnover analysis showed that addition of 6 aa converted myc UBB ϩ1 from a very stable protein into a short-lived protein that was degraded within 10 min (Fig. 5C ). These data confirms that the cause for the unusual stability of UBB ϩ1 lies in the limited length of the extension.
DISCUSSION
In this study, we investigated the molecular mechanisms underlying the unusual stability of the natural occurring UFD substrate UBB ϩ1 , an aberrant ubiquitin fusion found in neurodegenerative disorders (9, 10) , as well as a number of non-neuronal pathologies (11-13). Our analysis not only shed light on the reason for the stability of UBB ϩ1 but revealed fundamental insights into how substrates are handled by the proteasome. Most important, we found that UFD substrates require a minimal length in order to be efficiently degraded by proteasomes. The mechanisms responsible for this length dependency appear to be conserved in eukaryotes, as the critical length for efficient proteasomal degradation was similar for budding yeast and human cells. Our data show that UFD substrates that do not fulfill this length requirement accumulate and have a general inhibitory effect on ubiquitin-dependent proteasomal degradation.
Our results suggest that proteasomes require a short polypeptide stretch protruding from the UFD signal in order to process the substrate. reported earlier that ubiquitin carrying a short 16-aa C-terminal tag was ubiquitylated, similar to authentic UFD substrates, but nevertheless stable in yeast. Recently, it was reported that ubiquitin is poorly degraded in vitro unless it is provided with a C-terminal extension consisting of a combined histidine and hemagglutinin tag of 25 aa (29) . These observations are in line with our finding that two unrelated UFD substrates require a minimal length of 20 and 25 aa, respectively, to accommodate proteasomal degradation. The unfolding of substrates at the proteasome is accomplished by the AAA-ATPases residing in the base of the 19S regulatory particle (30) and is completed prior to substrate translocation and peptide hydrolysis (31, 32). It has been shown that a short unfolded structure is required for initiation of proteasomal degradation (33) . Since it is not only the eukaryotic proteasome that requires an unfolded structure for degradation, but also remotely related bacterial compartmentalized proteases (34) , this length limitation may reflect a fundamental physical constraint of such proteases independent of the targeting system that is used.
An important question is whether the length dependency found for UFD substrates also applies to other ubiquitin-dependent proteasome substrates. Unfortunately, it is technically impossible at this point to directly address this question. The UFD substrates are unique in the sense that the first ubiquitin in the polyubiquitin chain is directly fused to the substrate (28) . Because of this feature short substrates consisting of only 20 -30 aa can be expressed in the context of a full-sized UFD protein. If a similar approach would be used for other types of substrates, this would require expression of a substrate of no longer than 20 -30 aa. Peptides of this length are known to be inherently unstable and rapidly degraded by tripeptidyl peptidase II and amino peptidases (35) and hence cannot be used to address this question. Notably, several conceptual insights into proteasomal degradation have been made with UFD substrates, such as the minimal ubiquitin chain required for degradation (36) , suggesting that UFD substrates are not very different from more conventional substrates. Also, when it comes to the minimal length requirement found in this study, it seems unlikely that this would reflect a UFD-specific feature. This notion is strongly supported by a recent study on ubiquitin-independent proteasomal degradation of ornithine decarboxylase (ODC) fusions (37). Takeuchi et al. (37) reported that ODC fusions need a loosely unstructured region of 20 -30 aa, which is very similar to the minimal length for UFD substrates. It is noteworthy that these substrates apply different targeting mechanisms and that their degradation pathways merge only at the level of the proteasome (38) . The fact that the length dependency is shared between proteasome substrates as diverse as UFD-and ODC-based substrate strongly argues that it reflects a general prerequisite for proteasomal degradation that also applies to other proteasome substrates irrespective of their targeting mechanism.
A number of proteins associate with the proteasome through the presence of an N-terminal ubiquitin-like (UbL) domain (39) . The UbL domain of Rad23 can be functionally replaced by an N-terminal uncleavable ubiquitin moiety (40) . Vice versa, some UbL domains can target proteins for proteasomal degradation (5, 41) . Thus, the functional difference between the uncleavable N-terminal ubiquitin moieties present in UFD substrates and UbL domains may be rather subtle, with other factors determining whether it functions as a proteasome binding motif or instead targets for proteasomal degradation. A number of UbL-containing proteins have been reported to be able to decelerate proteasomal degradation. Recently, Finley and co-workers (42) reported that the deubiquitylation enzyme Ubp6 delays ubiquitin-dependent proteasomal degradation independent of its catalytic activity. Also, the UbL-containing protein Rad23 can impair the ubiquitin/proteasome system under in vitro conditions (43) . Rad23 is safeguarded from proteasomal degradation through a ubiquitin associated domain (UBA) domain, which functions as an intrinsic stabilization signal (5) . High levels of another UbL-UBA-containing protein, Dsk2, also lead to severe cellular defects and inhibition of proteolysis (44) . We propose that the inhibitory potential observed in these studies may be a common characteristic of proteins that interact with the proteasome by a UbL or UFD signal but resist proteasomal degradation. The unusual stability of these fusions is unlikely to be due to poor proteasomal targeting since enhancing targeting of UBB ϩ1 for proteasomal degradation by insertion of additional UFD signals (18) does not result in accelerated degradation, but on the contrary, further enhanced its inhibitory effect on ubiquitin-dependent proteolysis (7) . Based on these observations, we postulated that UBB ϩ1 is a difficult substrate that can frustrate the ubiquitin/proteasome system (7). Although our data show that proteasomal degradation of UBB ϩ1 is problematic, it is not impossible, as cells manage to clear low levels of the protein by proteasomal degradation (7). However, elevated UBB ϩ1 levels (7, 21, 27) or moderately reduced activity of the ubiquitin/proteasome system (20) triggers a rapid accumulation and stabilization of UBB ϩ1 , which in turn causes general dysfunction of the ubiquitin/proteasome system (7, 23, 24) . Even though our data explain the unusually slow turnover of UBB ϩ1 and show that the exceptional stability of UBB ϩ1 is crucial to its inhibitory effect on the ubiquitin/proteasome system, the exact mechanism responsible for its inhibitory activity remains open. While many questions remain unanswered regarding the precise role of UBB ϩ1 in neurodegeneration, this atypical UFD substrate has revealed new insights into the prerequisites for efficient proteasomal degradation. We demonstrated that the inhibitory activity attributed to this protein can be recapitulated by expression of an unrelated equally short UFD substrate. It is striking and ironic that, although N-terminal ubiquitin fusions have been routinely used in experimental settings as a robust way to target recombinant proteins for ubiquitin-dependent proteasomal degradation, the only presently identified natural occurring UFD substrate, i.e., UBB ϩ1 , is not only a poor proteasome substrate but its presence has a general inhibitory effect on the ubiquitin/proteasome system.
